The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison

Tariq, Arsalan; Kwok, Michael; Pearce, Adam; Rhee, Handoo; Kyle, Samuel; Marsh, Phillip; Raveenthiran, Sheliyan; Wong, David; McBean, Rhiannon; Westera, Jurjen; Dunglison, Nigel; Esler, Rachel; Navaratnam, Anojan; Yaxley, John; Thomas, Paul; Pattison, David A.; Roberts, Matthew J.

doi:10.1016/j.urolonc.2021.11.006

Cited by 24 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In three patients, PET imaging had an important impact on clinical decision making. Concordant FDG and PSMA uptake in metastatic RCC lesions was observed in 82% of cases, with the remaining two cases showing discordant uptake favoring PSMA [ 31 ].…”

Section: Psma Pet/ct In Clear Cell Renal Cell Carcinomamentioning

confidence: 99%

“…Several studies report the inclusion of patients affected by non-ccRCC [ 24 , 26 , 28 , 31 , 32 ], but larger case series regarding the performance of PSMA PET/CT in these patients remains very limited. Only one series has been published to date in which patients with papillary RCC ( n = 3), chromophobe RCC ( n = 2), unclassified RCC ( n = 2), and Xp11 translocation RCC ( n = 1) were included [ 33 ].…”

Section: Psma Pet/ct In Non-clear Cell Renal Cell Carcinomamentioning

confidence: 99%

“…As one might expect, the literature about therapy response monitoring with PSMA PET/CT in RCC is also scarce. Mittlmeier et al reported on 18 F-PSMA-1007 PET in a response evaluation of both tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) [ 31 ]. The 18 F-PSMA-1007 PET tracer, along with conventional CT scanning, was used in mRCC patients prior to the initiation of systemic treatment and was repeated 8 weeks after therapy initiation.…”

Section: Therapy Response Monitoringmentioning

confidence: 99%

“…As several studies show, staging and restaging with PSMA-targeted PET/CT may assist in clinical decision making and in selecting patients for metastasis-directed therapy [ 27 , 28 ]. Furthermore, as demonstrated by Mittlmeier et al, PSMA PET may play a role in early response monitoring of TKI and ICI treatment [ 31 ]. Intriguingly, changes in the intensity of PSMA uptake during systemic therapy might provide early response assessment or novel insight into the biological responses to treatment.…”

Section: Future Perspectives Of Psma Pet In Rccmentioning

confidence: 99%

See 3 more Smart Citations

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Muselaers

Erdem

Bertolo

et al. 2022

JCM

View full text Add to dashboard Cite

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.

show abstract

Section: Psma Pet/ct In Clear Cell Renal Cell Carcinomamentioning

confidence: 99%

Section: Psma Pet/ct In Non-clear Cell Renal Cell Carcinomamentioning

confidence: 99%

Section: Therapy Response Monitoringmentioning

confidence: 99%

Section: Future Perspectives Of Psma Pet In Rccmentioning

confidence: 99%

See 2 more Smart Citations

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Muselaers

Erdem

Bertolo

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In particular, [ 68 Ga]-PSMA and FDG PET findings were concordant in 6 out of 8 patients, although [ 68 Ga]-PSMA showed higher uptake in two additional lesions that changed patient's management from stereotactic radiotherapy to systemic chemotherapy. Likewise, [ 68 Ga]-PSMA and FDG PET/CT were mostly concordant for evaluation of primary tumor and metastatic disease in another study with 11 RCC patients (Tariq et al 2021). Furthermore, dual tracer PET/CT outperformed the conventional imaging in 5 out of 11 patients (45%), detecting more lesions in 2 patients and refuting positive lesions with conventional imaging in another 3 patients.…”

Section: Psma Pet/ct In Rcc Diagnosis and Stagingmentioning

confidence: 77%

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives

Urso

Castello

Rocca

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Renal masses detection is continually increasing worldwide, with Renal Cell Carcinoma (RCC) accounting for approximately 90% of all renal cancers and remaining one of the most aggressive urological malignancies. Despite improvements in cancer management, accurate diagnosis and treatment strategy of RCC by computed tomography (CT) and magnetic resonance imaging (MRI) are still challenging. Prostate-Specific Membrane Antigen (PSMA) is known to be highly expressed on the endothelial cells of the neovasculature of several solid tumors other than prostate cancer, including RCC. In this context, recent preliminary studies reported a promising role for positron emission tomography (PET)/CT with radiolabeled molecules targeting PSMA, in alternative to fluorodeoxyglucose (FDG) in RCC patients. Purpose The aim of our review is to provide an updated overview of current evidences and major limitations regarding the use of PSMA PET/CT in RCC. Methods A literature search, up to 31 December 2021, was performed using the following electronic databases: PubMed, SCOPUS, Web of Science, and Google Scholar. Results The findings of this review suggest that PSMA PET/CT could represent a valid imaging option for diagnosis, staging, and therapy response evaluation in RCC, particularly in clear cell RCC. Conclusions Further studies are needed for this “relatively” new imaging modality to consolidate its indications, timing, and practical procedures.

show abstract

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Pathmanathan,

Tariq,

Pearce

et al. 2023

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Purpose There is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC). Methods A retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment. Results

show abstract

The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison

Cited by 24 publications

References 26 publications

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Contact Info

Product

Resources

About